Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0502
-0.0006 (-1.18%)
At close: Oct 31, 2025

Adaptimmune Therapeutics Statistics

Total Valuation

ADAPY has a market cap or net worth of 13.46 million. The enterprise value is 36.08 million.

Market Cap13.46M
Enterprise Value 36.08M

Important Dates

The next estimated earnings date is Thursday, November 13, 2025.

Earnings Date Nov 13, 2025
Ex-Dividend Date n/a

Share Statistics

ADAPY has 265.05 million shares outstanding. The number of shares has increased by 8.53% in one year.

Current Share Class n/a
Shares Outstanding 265.05M
Shares Change (YoY) +8.53%
Shares Change (QoQ) +2.75%
Owned by Insiders (%) 0.65%
Owned by Institutions (%) 13.61%
Float 203.10M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.21
PB Ratio -0.19
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -0.21
EV / Sales 0.55
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -0.19

Financial Position

The company has a current ratio of 1.52

Current Ratio 1.52
Quick Ratio 1.07
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF -0.25
Interest Coverage -26.10

Financial Efficiency

Return on equity (ROE) is -1,341.10% and return on invested capital (ROIC) is -152.32%.

Return on Equity (ROE) -1,341.10%
Return on Assets (ROA) -40.86%
Return on Invested Capital (ROIC) -152.32%
Return on Capital Employed (ROCE) -186.89%
Revenue Per Employee 128,626
Profits Per Employee -335,486
Employee Count506
Asset Turnover 0.29
Inventory Turnover 20.28

Taxes

In the past 12 months, ADAPY has paid 3.71 million in taxes.

Income Tax 3.71M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -92.80% in the last 52 weeks. The beta is 2.49, so ADAPY's price volatility has been higher than the market average.

Beta (5Y) 2.49
52-Week Price Change -92.80%
50-Day Moving Average 0.10
200-Day Moving Average 0.27
Relative Strength Index (RSI) 37.50
Average Volume (20 Days) 123,710,358

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 0.28

Income Statement

In the last 12 months, ADAPY had revenue of 65.09 million and -169.76 million in losses. Loss per share was -0.66.

Revenue65.09M
Gross Profit -63.61M
Operating Income -147.87M
Pretax Income -166.05M
Net Income -169.76M
EBITDA -137.24M
EBIT -147.87M
Loss Per Share -0.66
Full Income Statement

Balance Sheet

The company has 26.06 million in cash and 48.68 million in debt, giving a net cash position of -22.62 million or -0.09 per share.

Cash & Cash Equivalents 26.06M
Total Debt 48.68M
Net Cash -22.62M
Net Cash Per Share -0.09
Equity (Book Value) -70.96M
Book Value Per Share -0.27
Working Capital 26.60M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -190.03 million and capital expenditures -1.64 million, giving a free cash flow of -191.67 million.

Operating Cash Flow -190.03M
Capital Expenditures -1.64M
Free Cash Flow -191.67M
FCF Per Share -0.72
Full Cash Flow Statement

Margins

Gross margin is -97.73%, with operating and profit margins of -227.19% and -260.82%.

Gross Margin -97.73%
Operating Margin -227.19%
Pretax Margin -255.12%
Profit Margin -260.82%
EBITDA Margin -210.86%
EBIT Margin -227.19%
FCF Margin n/a

Dividends & Yields

ADAPY does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -8.53%
Shareholder Yield -8.53%
Earnings Yield -1,260.76%
FCF Yield -1,423.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

ADAPY has an Altman Z-Score of -15.04. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -15.04
Piotroski F-Score n/a